Cargando…

CLRM-16 PATIENT-FOCUSED DRUG DEVELOPMENT IN NEURO-ONCOLOGY: A PILOT STUDY OF QUALITATIVE PATIENT INTERVIEWS EMBEDDED WITHIN A NEUROFIBROMATOSIS 2 CLINICAL TRIAL

BACKGROUND: The Food and Drug Administration recently issued guidance on conducting qualitative research to support patient-focused drug development. In prior FDA submissions, qualitative data has been critical to demonstrate the content validity of and meaningfulness of change in quantitative trial...

Descripción completa

Detalles Bibliográficos
Autores principales:	Merker, Vanessa, Von Imhof, Liesel, Park, Elyse, Babovic-Vuksanovic, Dusica, NghiemPhu, PhiOanh [Leia], Yohay, Kaleb, Plotkin, Scott
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Supplement Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354217/ http://dx.doi.org/10.1093/noajnl/vdac078.036

Ejemplares similares

Awareness and agreement with neurofibromatosis care guidelines among U.S. neurofibromatosis specialists
por: Merker, Vanessa L., et al.
Publicado: (2022)

COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis
por: Banerjee, Jineta, et al.
Publicado: (2023)

CLRM-01 SUMMARY OF VIRTUAL TUMOR BOARD PLATFORMS AND IMPLEMENTATION IN NEURO-ONCOLOGY
por: Ekhator, Chukwuyem, et al.
Publicado: (2022)

CLRM-11. BENCH TO BEDSIDE NEURO-ONCOLOGY: ADVOCATING FOR A CLINICALLY RELEVANT STRATEGY AS UNDERSCORED BY THE PANDEMIC
por: Brown, Timothy, et al.
Publicado: (2021)

A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas
por: Nghiemphu, Phioanh Leia, et al.
Publicado: (2012)

Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation
por: Legius, Eric, et al.
Publicado: (2021)

The Use of MEK Inhibitors in Neurofibromatosis Type 1–Associated Tumors and Management of Toxicities
por: Klesse, Laura J., et al.
Publicado: (2020)

Genetic testing for hearing loss in the United States should include deletion/duplication analysis for the deafness/infertility locus at 15q15.3
por: Hoppman, Nicole, et al.
Publicado: (2013)

Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone
por: Babovic-Vuksanovic, Dusica, et al.
Publicado: (2004)

Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis
por: Merker, Vanessa L., et al.
Publicado: (2018)

Long‐Term Outcomes in Patients With Turner Syndrome: A 68‐Year Follow‐Up
por: Fuchs, Margaret M., et al.
Publicado: (2019)

Neurofibromatosis 2011: a report of the Children’s Tumor Foundation Annual Meeting
por: Kalamarides, Michel, et al.
Publicado: (2011)

CLRM-07 RANO 2.0: PROPOSAL FOR AN UPDATE TO THE RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (RANO) CRITERIA FOR HIGH- AND LOW-GRADE GLIOMAS IN ADULTS
por: Wen, Patrick, et al.
Publicado: (2023)

Incidental parenchymal magnetic resonance imaging findings in the brains of patients with neurofibromatosis type 2()
por: Vargas, Wendy S., et al.
Publicado: (2014)

The impact of the COVID-19 pandemic on neurofibromatosis clinical care and research
por: Radtke, Heather B., et al.
Publicado: (2021)

CLRM-08. TRIAL WORKING GROUPS FOR PAEDIATRIC BRAIN TUMOURS
por: Rahman, Ruman, et al.
Publicado: (2021)

Novel NR2F1 variants likely disrupt DNA binding: molecular modeling in two cases, review of published cases, genotype–phenotype correlation, and phenotypic expansion of the Bosch–Boonstra–Schaaf optic atrophy syndrome
por: Kaiwar, Charu, et al.
Publicado: (2017)

CLRM-18 SCREEN FAILURES IN PHASE III GLIOBLASTOMA CLINICAL TRIALS
por: Peters, Katherine
Publicado: (2022)

NFB-21. Neurofibromatosis Type I in the Setting of Neuro-Oncology
por: Hemenway, Molly
Publicado: (2022)

CLRM-13. INTRAOPERATIVE MICRODIALYSIS: GLIOMA INTELLIGENCE FROM BEHIND ENEMY LINES
por: Riviere-Cazaux, Cecile, et al.
Publicado: (2021)

CLRM-11 CURRENT STATE OF CLINICAL TRIALS FOR PATIENTS WITH MELANOMA BRAIN METASTASES
por: Elghawy, Omar, et al.
Publicado: (2022)

CLRM-20 IDENTIFYING RISK FACTORS AND ANALYZING SURVIVAL FOLLOWING PACHYMENINGEAL FAILURE
por: Kalyvas, Aristotelis, et al.
Publicado: (2022)

Quantitative Assessment of Whole-Body Tumor Burden in Adult Patients with Neurofibromatosis
por: Plotkin, Scott R., et al.
Publicado: (2012)

Pathogenic mutations in the chromokinesin KIF22 disrupt anaphase chromosome segregation
por: Thompson, Alex F, et al.
Publicado: (2022)

CLRM-05. DRUG-RELEASING MICRODEVICES TO PREDICT RESPONSES TO TARGETED THERAPIES IN PATIENTS WITH GLIOMAS
por: Blitz, Sarah, et al.
Publicado: (2021)

CLRM-12. HYBRID DESIGNS FOR USING EXTERNAL CONTROLS IN PHASE 3 GLIOBLASTOMA TRIALS
por: Polley, Mei-Yin, et al.
Publicado: (2021)

CLRM-19 USING FUNCTIONAL PRECISION MEDICINE TO GUIDE CLINICAL TRIAL ENROLLMENT IN GBM
por: Ledford, Aubrey, et al.
Publicado: (2022)

CLRM-01 DETERMINANTS OF SYMPTOMATIC INTRACRANIAL PROGRESSION FOLLOWING AN INITIAL STEREOTACTIC RADIOSURGERY COURSE
por: Leng, Jim, et al.
Publicado: (2023)

CLRM-09 MAPPING THE DISTRIBUTION AND CLINICAL ASSOCIATIONS OF BRAIN METASTASES IN RENAL CELL CARCINOMA
por: Kamson, David Olayinka, et al.
Publicado: (2023)

CLRM-01. MACHINE LEARNING TO UNCOVER SIGNATURES OF VULNERABILITY IN GLIOBLASTOMA UMBRELLA SIGNATURE TRIAL (GUST)
por: Peng, Sen, et al.
Publicado: (2021)

CLRM-09. INCORPORATING EXTERNAL CONTROL ARM IN MDNA55 RECURRENT GLIOBLASTOMA REGISTRATION TRIAL
por: Davi, Ruthanna, et al.
Publicado: (2021)

CLRM-05 FEASIBILITY OF EVALUATING ABEMACICLIB NEUROPHARMACOKINETICS OF DIFFUSE MIDLINE GLIOMA USING INTRATUMORAL MICRODIALYSIS
por: Dalmage, Mahalia, et al.
Publicado: (2022)

CLRM-14 INTRATUMORAL EXTRACELLULAR METABOLIC IMPACT OF DFMO AND AMXT 1501 IN LIVE HUMAN GLIOMAS
por: Riviere-Cazaux, Cecile, et al.
Publicado: (2022)

An intragenic duplication of TRPS1 leading to abnormal transcripts and causing trichorhinophalangeal syndrome type I
por: Zepeda-Mendoza, Cinthya J., et al.
Publicado: (2019)

The Future Glioblastoma Clinical Trials Landscape: Early Phase 0, Window of Opportunity, and Adaptive Phase I–III Studies
por: Cho, Nicholas S., et al.
Publicado: (2023)

CLRM-03 INCIDENCE OF INTRACRANIAL HEMORRHAGE IN GLIOMA PATIENTS WITH VENOUS THROMBOEMBOLISM CONVERTED FROM LMWH TO APIXABAN
por: Aboud, Orwa, et al.
Publicado: (2022)

CLRM-17 USE OF EXTERNAL CONTROL DATA FOR PLANNING AND ANALYZING GBM TRIALS: READY FOR PRIME TIME?
por: Polley, Mei-Yin, et al.
Publicado: (2022)

CLRM-08 TAILORING CLINICAL TRIALS TO INCREASE PATIENT ENGAGEMENT: IMPACT ON PATIENT-REPORTED OUTCOMES IN ONCOLOGY
por: Khakwani, Saima, et al.
Publicado: (2023)

CLRM-02 CALCIFIED SPINAL MENINGIOMAS: A SYSTEMATIC REVIEW OF CLINICAL CHARACTERISTICS, TREATMENT STRATEGIES, AND OUTCOMES
por: Reddy, Raghuram, et al.
Publicado: (2023)

Targeted next-generation sequencing of 565 neuro-oncology patients at UCLA: A single-institution experience
por: Ji, Matthew S, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q1bejovo8bgridbfunlsi2t4k0